New combo therapy aims to stall sarcoma progression
NCT ID NCT04028063
First seen Jan 30, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This study tests whether adding two immunotherapy drugs (zalifrelimab or botensilimab plus balstilimab) to standard chemotherapy (doxorubicin) can keep advanced soft tissue sarcoma from growing longer than chemo alone. About 65 adults with sarcoma that has spread or cannot be removed by surgery will receive the combination. The main goal is to see how many patients are alive without their cancer getting worse after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.